Attana Application Note: Early detection of clinical failure

Dokument -

Attana Application Note: Early detection of clinical failure

The objective of this application note was to evaluate newly developed therapeutic antibodies in a biologically relevant context (cells) in order to detect failing candidates at an earlier stage. Among other things, it was found that real-time screening of drug candidates in a synthetic and in a cellular context together provides highly informative and biologically relevant data.
go to media item
Licens:
Medieanvändning
Innehållet får laddas ner, användas och delas i olika mediekanaler av t.ex. journalister, bloggare, krönikörer, opinionsbildare etc., i syftet att förmedla, redogöra för och kommentera ert pressmeddelande, inlägg eller information, så länge innehållet används oförändrat och i dess helhet. Upphovsmannen ska anges i den omfattning och på det sätt god sed kräver (vilket bl.a. innebär att fotografer till bilder nästan alltid måste anges).
Filformat:
.pdf
Ladda ner

Ämnen

  • Medicinsk forskning

Kategorier

  • cell
  • attana cell 200
  • biosensor

Relaterat innehåll

  • Biosensor- Attana Cell 200, label free, real time kinetics on cells

    Revolutionary Swedish invention can potentially improve drug development! Attana AB introduces the Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body.

  • Fight against cancer - Attana's collaborator interviewed

    Attana's collaborator at Gothenburg University, Dr. Sture Lindegren, is interviewed about a possible new cure for ovarian cancers. Using the Attana Cell 200 instrument, Dr. Lindegren and his team are testing antibodies as carriers of radionuclide that target cancer cells directly instead of affecting the whole body as current cancer therapies do.

  • PEGS 2010 with Attana!

    We are happy to have met so many industry people during the Protein Engineering Summit 2010 in Boston last week, and if you were there but didn't get the chance to taste our exquisite espresso you are welcome to stop by our booth during our upcoming events!

  • PEGS 2010 with Attana!

    We are happy to have met so many industry people during the Protein Engineering Summit 2010 in Boston last week, and if you were there but didn't get the chance to taste our exquisite espresso you are welcome to stop by our booth during our upcoming events!

  • Attana's Story told by CEO and co-founder Dr. Teodor Aastrup

    When we founded Attana in 2002, we had a dream of creating a tool that could mimic reality. We were set to do this by developing an instrument capable of measuring biological interactions exactly as the actual events in the human body.

  • Fight against cancer - Attana's collaborator interviewed

    Attana's collaborator at Gothenburg University, Dr. Sture Lindegren, is interviewed about a possible new cure for ovarian cancers. Using the Attana Cell 200 instrument, Dr. Lindegren and his team are testing antibodies as carriers of radionuclide that target cancer cells directly instead of affecting the whole body as current cancer therapies do.

  • PEGS 2011 with Attana!

    We are pleased to have met so many like minded members of industry during the Protein Engineering Summit 2011 in Boston last week. If you were there but didn't get the chance to taste our exquisite espresso you are always welcome to stop by our booth during our upcoming events!